| | | Join HNCA for a Free Screening of "Can You Hear My Voice?" and an Exclusive Q&A |
|
|
| | Join HNCA, the THANC Foundation, and Atos for a free film screening. "Can You Hear My Voice?" follows the one-of-a-kind Shout at Cancer choir, whose members have all had their voice boxes removed, as they prepare for their most ambitious concert: a sold-out performance at London’s historic Tabernacle theater. The film includes energetic performances of songs popularized by Nina Simone, Tears for Fears, and Louis Armstrong, all backed by the stellar Peter Edwards Jazz Trio and a saxophone quartet. Along the way, choir members’ cancer stories unfold, revealing their struggles with self-identity and loss encountered on the road to survivorship. “Can You Hear My Voice?” triumphantly illuminates the human capacity for resilience in the face of overwhelming adversity. While the film follows this inspiring group of laryngectomees, its larger message is one of survivorship, the role of attitude and holistic well-being during and after cancer, and the psychosocial aspects of living in survivorship. We encourage everyone who is interested to take advantage of this opportunity! The film is produced and directed by Bill Brummel (Peabody Award, 2-time International Documentary Association Award winner, and 5-time Emmy Award nominee). It’s Brummel’s first film since having his own voice box removed in 2016. | Register now using the button below to view the film online at your convenience from September 9 - 18, 2021. And join us for an exclusive Q&A zoom session on September 14, 2021, at 1:00 pm Eastern. Join HNCA, Bill Brummel, and his personal physician, Dr. Uttam Sinha. Dr. Sinha. Hear more about Bill's journey, the inspiration for the film, and ask your questions about life as a cancer survivor, laryngectomee, and the inspiration for the film. | | |
| | |
|
| Oral, Head and Neck Cancer Awareness Week Returns this November |
|
|
| November is Mouth Cancer Action Month, and Head and Neck Cancer Alliance is gearing up to host an Awareness Week from November 7 – 13. For more than two decades, HNCA and our medical and dental partners have worked together to raise awareness and save lives by hosting community health screenings to encourage early detection during our April Oral, Head and Neck Cancer Awareness Week. We now look forward to teaming up with hospitals, medical & dental clinics, and community organizations worldwide to provide oral, head and neck cancer screenings and awareness events during our fall Awareness Week. Medical and dental clinics may now register their screenings or educational events through HNCA. This registration is open ONLY to hospitals, medical & dental clinics, medical facilities, and community organizations hosting health fairs; registration is not open to individuals. As always, HNCA provides promotional and educational materials, and the screening sites organize the staff and volunteers. Registered sites will receive a screening kit that includes volunteer t-shirts, HIPAA-Certified screening forms, educational materials, giveaways, and more. Screening Kits begin shipping in mid-October 2021. We understand many sites may have challenges with hosting a public screening due to COVID-19 restrictions, so we are encouraging sites to: -
Our screening partners can also get involved in other ways, such as participating in our online awareness-raising campaign, hosting a virtual educational activity, or sharing OHANCAW print and digital materials in their waiting and exam rooms. -
Share this email with dental offices in your local community who are currently seeing patients and can serve as the first line of defense in detecting head and neck cancer. If you’re unable to host a screening in November, please consider hosting an event at another time. We hope to resume our usual schedule for public screenings during Oral, Head and Neck Cancer Awareness Week, April 3- 9, 2022. |
| This program is generously supported by grants from |
|
|
| | |
|
| | Upcoming Webinars Help Cancer Patients Navigate Medicare and Health Insurance Are you or a loved one facing cancer and wondering how to navigate through the Medicare or health insurance systems? Triage Cancer is offering the following webinars that may help! |
| Medicare September 15, 2021 | 1:00 - 2:30 pm Eastern This FREE webinar is part of the Triage Cancer Webinar Series, which will explore the basics of the Medicare system. Attendees will learn about the different parts of Medicare, the different financial assistance options available to individuals on Medicare, and the various Medicare enrollment periods. Presented by Monica Bryant, Esq. |
| |
|
| Understanding Health Insurance October 14, 2021 | 1:00 - 2:30 pm Eastern This FREE webinar is part of the Triage Cancer Webinar Series, which will explore how to choose and use your health insurance. Attendees will learn about the various healthcare and health insurance options available to individuals diagnosed with cancer, how patients can effectively choose between plan options, and the appeal process. Presented by Monica Bryant, Esq. |
| |
|
| | | The Future of Head and Neck Cancer: Emerging Treatments, Clinical Trials, and Research Studies *Sponsor Content | Learn HNCA's stance on corporate support below. |
| HNCA’s work would not be possible without our sponsors and partners. Please see below to learn more about our partners and the clinical trials that are underway to help head and neck cancer patients. For more information about clinical trials and where to find trials that might apply to you or a loved one, visit our Clinical Trial Finder or click on any of the trial opportunities below. |
|  | |
|
| | |  | Rakuten Medical’s global Phase 3 multi-center clinical trial with ASP-1929 to evaluate its efficacy and safety in patients with recurrent head and neck squamous cell carcinoma. ASP-1929 photoimmunotherapy is a combination drug and device anticancer treatment that utilizes a cetuximab monoclonal antibody conjugated to a photoactivatable dye that can be excited upon localized nonthermal 690 nm red light illumination to induce rapid cell death of target tumor cells. In the ASP-1929-301 study, enrolled patients will be randomized in a 2:1 fashion to receive either ASP-1929 photoimmunotherapy or physician’s choice standard of care (methotrexate, docetaxel, paclitaxel or cetuximab). The study is actively enrolling in 3 regions: Taiwan, Japan and the United States. ClinicalTrials.gov Identifier: NCT03769506 |
| |
|
| | | *Statement on Sponsor Content and Corporate Support: The information published on this website and in our materials is intended to educate you about Oral, Head and Neck Cancer. The content is not intended to take the place of a discussion with a qualified physician who is familiar with your medical situation. It is important to remember that each individual is different, and the reasons for—and outcomes of—any treatment plan depends on the patient's individual condition. If you have questions or concerns after reading any information on this website or in our materials, you should discuss them openly and honestly with your physician. Any products and manufacturers included on this site are presented for informational purposes only and do not constitute product approval or endorsement by HNCA. The content provided by HNCA is in no way intended to be a substitute for medical consultation with a qualified professional. HNCA encourages those using its resources to be careful when evaluating medical information or products. If you are unsure about your medical condition, consult a physician. Funding from our corporate partners supports HNCA’s programs and educational initiatives, and HNCA maintains independence in its design of programs, content, and initiatives. |
|
|
| | | Thank You to our Corporate and Community Partners |
|  | | | | |
|
| | Head and Neck Cancer Alliance
PO BOX 21688 | Charleston, South Carolina 29413
866-792-4622 | info@headandneck.org |
| | Be sure to add our email address to your address book or safe senders list so our emails get to your inbox. Having trouble viewing this email? View it in your web browser |
|
|
| |
|
|
